Pharmacokinetics of recombinant interferon (IFN)-alpha in a hepatitis patient with neutralizing antibody to IFN

被引：4

作者：

Antonelli, G

Simeoni, E

Artini, M

Turriziani, O

Dianzani, F

机构：

[1] INST VIROL,I-00185 ROME,ITALY

[2] UNIV PISA,DEPT BIOMED,I-56127 PISA,ITALY

[3] UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO I,MED CLIN 1,I-00161 ROME,ITALY

来源：

HEPATOLOGY RESEARCH | 1997年 / 8卷 / 03期

关键词：

interferon; hepatitis; hepatitis C; antibody to interferon; breakthrough; interferon pharmacokinetics;

D O I：

10.1016/S1386-6346(97)00065-X

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Pharmacokinetics of recombinant (r) interferon (IFN)-alpha 2 was examined in a hepatitis C patient seropositive for neutralizing antibodies to rIFN-alpha 2. The results of the experiments showed that antibody to IFN developed during therapy in this patient restricted the bioavailability of the administered IFN. Since the achievement of IFN effective concentration in the tissues implies definite IFN plasma levels, it can be suggested that the presence of circulating antibody to IFN may affect its therapeutic efficacy. (C) 1997 Elsevier Science Ireland Ltd.

引用

页码：149 / 155

页数：7

共 18 条

[1] Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha 2 therapy [J].